Xie C, Wang X, Young RL, Horowitz M, Rayner CK, Wu T
However, the dual GIP receptor (GIPR)/GLP-1R agonist, tirzepatide, has demonstrated superior efficacy in reducing HbA 1c and body weight in people with type 2 diabetes [5]
The manufacturer recommends three primary areas: The Abdomen: At least two inches away from the belly button
(NOTE: While Retatrutide itself has not been directly studied for its effects on energy expenditure, the medical literature shows glucagon infusions on its own can increase it in humans all the more reason you should pay attention to the Phase 1 clinical trial measuring calorie consumption in Retatrutide users) Gone was the appetite suppression, and in came the appetite elevation
This classification means there are stricter regulations on how it can be prescribed and dispensed